Evidence map›Paper›PMID 33828176›Full record

ArticleScientific reports2021

Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay.

Shiqin Liu, Fernando Garcia-Marques, Chiyuan Amy Zhang, Jordan John Lee, Rosalie Nolley, Michelle Shen, En-Chi Hsu, Merve Aslan, Kashyap Koul, Sharon J Pitteri and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels ofInternational journal of molecular sciences · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shiqin LiuDepartment of Radiology, Stanford University, Stanford, CA, USA.
Fernando Garcia-MarquesDepartment of Radiology, Stanford University, Stanford, CA, USA.
Chiyuan Amy ZhangDepartment of Urology, Stanford University, Stanford, CA, USA.
Jordan John LeeDepartment of Radiology, Stanford University, Stanford, CA, USA.
Rosalie NolleyDepartment of Urology, Stanford University, Stanford, CA, USA.
Michelle ShenDepartment of Radiology, Stanford University, Stanford, CA, USA.
En-Chi HsuDepartment of Radiology, Stanford University, Stanford, CA, USA.
Merve AslanDepartment of Radiology, Stanford University, Stanford, CA, USA.
Kashyap KoulDepartment of Radiology, Stanford University, Stanford, CA, USA.
Sharon J PitteriDepartment of Radiology, Stanford University, Stanford, CA, USA.
James D BrooksCanary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, USA.
Tanya StoyanovaDepartment of Radiology, Stanford University, Stanford, CA, USA. stanya@stanford.edu.
Stanford University · US

Funding

Stanford Molecular and Cellular Characterization LaboratoryU01CA196387 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2020
$5.2M
Elucidating the Role of Trop2 in Prostate CancerR37CA240822 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2020 to 2026
$2.5M
Elucidating the Role of UCHL1 in Aggressive Prostate CancerR01CA244281 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI STOYANOVA, TANYA I · 2020 to 2024
$1.8M
DESI-MS detection of positive margins in kidney cancerR21CA229933 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D., ZARE, RICHARD N · 2018 to 2019
$369k
NCI NIH HHS R01 CA244281NCI NIH HHS R21 CA229933NCI NIH HHS R37 CA240822NCI NIH HHS U01 CA196387
6 · The paper itself

Abstract

Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples from ten men with high-grade and high-volume prostate cancer. Our study identified six (CASP8, MSLN, FGFBP1, ICOSLG, TIE2 and S100A4) out of 174 proteins that were significantly decreased after radical prostatectomy. High levels of CASP8 were detected in pre-operative serum samples when compared to post-operative serum samples and serum samples from patients with benign prostate hyperplasia (BPH). By immunohistochemistry, CASP8 protein was expressed at higher levels in prostate cancer tissues compared to non-cancerous and BPH tissues. Likewise, CASP8 mRNA expression was significantly upregulated in prostate cancer when compared to benign prostate tissues in four independent clinical datasets. In addition, mRNA levels of CASP8 were higher in patients with recurrent prostate cancer when compared to patients with non-recurrent prostate cancer and high expression of CASP8 was associated with worse disease-free survival and overall survival in renal cancer. Together, our results suggest that CASP8 may potentially serve as a biomarker for high-risk prostate cancer and possibly renal cancer.

Indexed as

AgedBiomarkers, TumorCaspase 8Disease-Free SurvivalHumansImmunoassayImmunohistochemistryImmunologic TestsMaleMesothelinMiddle AgedNeoplasm Recurrence, LocalProstateProstatectomyProstate-Specific AntigenProstatic HyperplasiaBiomarkers, TumorCASP8 protein, humanCaspase 8MesothelinMSLN protein, humanProstate-Specific Antigen

Identifiers

PMID33828176
PMCPMC8027881
OpenAlexW3149779724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.